Knowthestock.com
ABEO - Abeona Therapeutics Inc

Sell

Weak GrowthEarnings/Profit is Negative
WeakStrong
WeakStrong

17%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -39.91%
Operating Income is Negative
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -1379.52%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 4.9
Debt Ratio is 0.58
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.2
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Abeona Therapeutics Inc (ABEO) - https://abeonatherapeutics.com/
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Exchange - NASDAQ
Industry - Research and Development in Biotechnology (except Nanobiotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Joao Siffert
Employees - 99
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.